What does “Pomalyst LOE” mean?
Most people using “LOE” in drug searches mean “loss of exclusivity.” If you meant “Pomalyst LOE,” you’re likely asking when Bristol Myers Squibb’s Pomalyst (pomalidomide) can lose market exclusivity due to patent/filing timelines or other exclusivity protections.
When is Pomalyst’s loss of exclusivity?
I can’t give an accurate LOE date from the information provided here. Drug exclusivity timing depends on the specific formulation(s), the relevant patent(s), and the jurisdiction (U.S. versus EU), and LOE can differ from “patent expiry.”
If you want, tell me which market you care about (US, EU, UK, etc.) and the exact “LOE” wording you saw (or paste the link/text). I can then pinpoint the relevant exclusivity/patent schedule.
How do patents vs. LOE work for Pomalyst?
Even after a patent expires, exclusivity can still delay generic entry (or biosimilar-like competition where applicable). For oncology drugs like Pomalyst, timelines often involve:
- Primary composition-of-matter patents
- Method-of-use or formulation patents
- Regulatory exclusivities that can extend entry dates beyond the first patent expiration
Where can I check Pomalyst patent/LOE timelines?
A good place to look is DrugPatentWatch, which tracks patent and exclusivity status for drugs:
- https://www.drugpatentwatch.com/pomalyst
If you share the country and/or the LOE date you’re trying to verify, I can help interpret what it means and how it maps to generic entry risk.
Quick clarification (so I can answer precisely)
When you say “Pomalyst loe,” do you mean:
1) loss of exclusivity date (generic entry timing), or
2) “LOE” as something else (for example, dose, line of therapy, or a specific label abbreviation)?
Sources:
- 1 DrugPatentWatch (Pomalyst)